Zhou MT, Zhang P, Mao Q, Wei XQ, Yang L, Zhang XM. Current research status of transarterial therapies for hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(9): 3752-3760 [PMID: 39350995 DOI: 10.4251/wjgo.v16.i9.3752]
Corresponding Author of This Article
Lin Yang, MD, Professor, Department of Radiology, Interventional Medical Center, Science and Technology Innovation Center, The Affiliated Hospital of North Sichuan Medical College, No.1 South Maoyuan Road, Nanchong 637000, Sichuan Province, China. linyangmd@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Mao-Ting Zhou, Peng Zhang, Qi Mao, Lin Yang, Xiao-Ming Zhang, Department of Radiology, Interventional Medical Center, Science and Technology Innovation Center, The Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China
Xiao-Qin Wei, School of Medical Imaging, North Sichuan Medical College, Nanchong 637000, Sichuan Province, China
Co-first authors: Mao-Ting Zhou and Peng Zhang.
Author contributions: Zhou MT and Zhang P contributed equally; Zhou MT, Zhang P, Mao Q, Wei XQ, Yang L and Zhang XM contributed to this paper; Yang L and Zhang XM designed the manuscript; and Zhou MT, Zhang P, Mao Q, Wei XQ and Yang L contributed to the writing and editing of the manuscript.
Supported bythe Project of City-University Science and Technology Strategic Cooperation of Nanchong City, No. 20SXQT0324.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lin Yang, MD, Professor, Department of Radiology, Interventional Medical Center, Science and Technology Innovation Center, The Affiliated Hospital of North Sichuan Medical College, No.1 South Maoyuan Road, Nanchong 637000, Sichuan Province, China. linyangmd@163.com
Received: March 11, 2024 Revised: May 22, 2024 Accepted: May 30, 2024 Published online: September 15, 2024 Processing time: 182 Days and 6.4 Hours
Abstract
With continuous advancements in interventional radiology, considerable progress has been made in transarterial therapies for hepatocellular carcinoma (HCC) in recent years, and an increasing number of research papers on transarterial therapies for HCC have been published. In this editorial, we comment on the article by Ma et al published in the recent issue of the World Journal of Gastrointestinal Oncology: “Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable HCC”. We focus specifically on the current research status and future directions of transarterial therapies. In the future, more studies are needed to determine the optimal transarterial local treatment for HCC. With the emergence of checkpoint immunotherapy modalities, it is expected that the results of trials of transarterial local therapy combined with systemic therapy will bring new hope to HCC patients.
Core Tip: Articles on transarterial therapies for hepatocellular carcinoma (HCC) were systematically reviewed. The results of this study showed that transarterial therapies combined with systemic therapy strategies are research hotspots in this field, and researchers dedicated to transarterial therapies for HCC should pay attention to these topics in the future.
